This is a particularly interesting possibility given that diet might be a significant contributing factor to ASD risk associated with TMLHE mutations
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
Jiang T, Zhou Y, Zhu J, Chen Z, Sun P, Zhang Q, et al
Metabolic Health Improvements in blood sugar, insulin sensitivity, and inflammatory markers are particularly valuable for women melanotan metabolic benefits
Large-Scale Study Data Most of the existing evidence about semaglutides effects on alcohol consumption comes from preclinical studies, observational research, and smaller phase 2 trials
Scottish Intercollegiate Guideline Network (SIGN)
